Primary Central Nervous System Tumors

Contact: Lawrence S. Chin, MD, Chair, Nuerosurgery Department
Phone: 315 464-4470 or
Regional Oncology Center
Phone: 315 464-8200

Eighty-five patients are treated annually at University Hospital for primary central nervous system tumors. The management of these patients is a collaborative effort by members of the departments of Neurosurgery, Neuroradiology, Neuropathology, Radiation Oncology, Medical Oncology and Pediatric Hematology-Oncology. The program encompasses the full range of modern neuro-oncologic treatment.

Neurosurgical capabilities include:

  • A dedicated Neurosurgical ICU
  • Awake craniotomies with cortical mapping
  • Endoscopic neurosurgery
  • Brachytheraphy with implantation of radioactive iodine seeds
  • A Lexall stereotactic frame for stereotactic biopsies
  • MKM frameless stereotactic microscope and localizing system to map and plan tumor resections.

The Department of Radiology provides state-of-the art CT and MRI imaging interpreted by board certified neuroradiologists, intraoperative ultrasound, angiography, and interventional procedures such as preoperative embolization of meningiomas.

The Department of Pathology provides a full range of histologic and immunohistochemical analyses by board certified neuropathologists for the accurate diagnosis of primary central nervous sytem tumors, which is essential to guide further therapy.

Radiation Oncology provides external beam radiotherapy using megavoltage linear accelerators, and, in collaboration with the Department of Neurosurgery, sterotatic linear radiosurgery and brachytherapy.

The Departments of Medical Oncology and Pediatric Hematology-Oncology provide conventional adjuvant chemotherapy and supportive care in the outpatient and inpatient settings, as well as experimental Phase I, Phase II and Phase III chemotherapy protocols through in-house studies, the Buffalo-Rochester Syracuse Neurooncology Research Group, and the Pediatric Oncology Group. Active collaborative bench research involving members of the Departments of Neurosurgery, Medical Oncology, Pediatric Hematology-Oncology, Radiation Oncology, Neurology, and Neuropathology is ongoing and relies heavily on tumor tissue and cell lines derived from clinical specimens from patients. Current studies include mapping double minute chromosomes in gliomas, the role epidural growth factor receptor in glioma and modulation of amplification of the gene for the receptor as a target for therapy; the use of epidural growth factor receptor amplification as a prognostic factor for chemotherapy response, the use of amofistine as a radioprotectant in childhood brain tumors, and the role of interferon inducible genes in glioma.